BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Litifilimab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Litifilimab\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06044337-5645@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20290626
DTEND;VALUE=DATE:20290627
SUMMARY:Litifilimab: Phase 3 readout est. (NCT06044337)
DESCRIPTION:Litifilimab\, phase 3.\nStudy: A Long-Term Extension Study to L
 earn More About the Safety of Litifilimab (BIIB059) Injections and Whether
  They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous
  Lupus Erythematosus\nEstimated primary completion: 26 June 2029. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/litifilimab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06044337
URL:https://assetmemo.bio/drug/litifilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05352919-5645@assetmemo.bio
DTSTAMP:20261121T005435Z
DTSTART;VALUE=DATE:20320503
DTEND;VALUE=DATE:20320504
SUMMARY:Litifilimab: Phase 3 readout est. (NCT05352919)
DESCRIPTION:Litifilimab\, phase 3\, Systemic Lupus Erythematosus.\nStudy: A
  Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) I
 njections and it's Effects on Symptoms in Adults With Systemic Lupus Eryth
 ematosus (SLE)\nEstimated primary completion: 3 May 2032. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/litifilimab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05352919
URL:https://assetmemo.bio/drug/litifilimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
